Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | EPIX |
---|---|---|
09:32 ET | 100 | 5.49 |
10:24 ET | 100 | 5.22 |
10:32 ET | 201 | 5.2149 |
11:38 ET | 1307 | 5.235 |
11:40 ET | 2092 | 5.25 |
11:44 ET | 100 | 5.23 |
11:45 ET | 100 | 5.24 |
12:14 ET | 100 | 5.33 |
01:17 ET | 200 | 5.27 |
01:24 ET | 151 | 5.335 |
02:44 ET | 9721 | 5.25 |
03:16 ET | 100 | 5.25 |
03:25 ET | 100 | 5.25 |
03:50 ET | 100 | 5.29 |
03:54 ET | 384 | 5.24 |
03:56 ET | 100 | 5.25 |
03:59 ET | 8963 | 5.34 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
ESSA Pharma Inc | 240.4M | -8.5x | --- |
Rezolute Inc | 240.5M | -4.1x | --- |
Zura Bio Ltd | 240.3M | -2.4x | --- |
Aldeyra Therapeutics Inc | 243.0M | -8.2x | --- |
Actinium Pharmaceuticals Inc | 235.3M | -4.5x | --- |
Gossamer Bio Inc | 246.6M | -1.1x | --- |
ESSA Pharma Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is focused on developing proprietary therapies for the treatment of patients with prostate cancer. Its lead candidate, EPI-7386, is an oral, small molecule that inhibits the N-terminal domain of the androgen receptor (AR). The Company is completing the initial Phase I clinical development of EPI-7386 as a monotherapy treatment for patients with metastatic castration-resistant prostate cancer (mCRPC). The Company is also developing ANITen bAsed Chimera (ANITAC) AR NTD degraders to suppress androgen biology.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $240.4M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 44.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.82 |
EPS | $-0.63 |
Book Value | $3.30 |
P/E Ratio | -8.5x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.